NCT00152997已完成2 期
A Randomised, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Pramipexole With the Dose Range From 0.125 mg to 0.75 mg Orally Once Daily for 6 Weeks in Patients With Primary Restless Legs Syndrome.
适应症
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 41
- 试验地点
- 7
- 主要终点
- Primary Endpoint: Decrease in periodic limb movements during time in bed index (PLMI) in the PSG
研究概览
简要总结
The objective of this trial is to investigate the efficacy and safety of pramipexole (0.125-0.75 mg) orally once daily as compared with placebo for 6 weeks in patients with primary restless legs syndrome (RLS) and to investigate the reliability of the Japanese version of the RLS rating scale by the International Restless Legs Syndrome Study Group (IRLSSG) as a sub-study.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double
入排标准
- 年龄范围
- 20 Years 至 80 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •According to the essential diagnostic criteria for RLS of NIH and IRLSSG, the following four all criterias must be presented:
- •An urge to move the legs, usually accompanied or caused by uncomfortable and unpleasant sensations in legs
- •The urge to move or unpleasant sensations begin or worsen during periods of rest or inactivity such as lying or sitting
- •The urge to move or unpleasant sensations are partially or totally relieved by movement, such as walking or stretching, at least as long as the activity continues
- •The urge to move or unpleasant sensations are worse in the evening or night than during the day or only occur in the evening or night
- •PLM (during time in bed) index of at least 5 per hour (in the worst affected leg) at Visit 3
- •Total score of RLS severity scale-Japanese version by IRLSSG > 15 at Visit 3
- •At least 1 time per week of RLS symptoms interfering with sleep within the last one month at Visit 1.
排除标准
- •Pre-menopausal women who meet any one of the following (1) - (3):
- •Pregnant or possibly pregnant
- •In lactation
- •Desire to be pregnant during study period Even when a patient was confirmed not to fall under the criteria above at initiation of study, if the patient is of childbearing potential, pregnancy tests should be performed when possible. If pregnancy test is positive, the investigational product should be discontinued.
- •Males not using an adequate form of contraception.
- •Patients who took the neuroleptics within 4 weeks before the screening Visit 1, or neuroleptic-induced akathisia.
- •Patients who can not stop the treatment with medication or dietary supplements, which could significantly influence RLS symptoms to wash-out at least 14 days before drug administration (refer to Appendix 3 for prohibited medication), e.g. dopaminergic drugs (levodopa or dopamine agonists) or antidopaminergic drugs (neuroleptics or metoclopramide etc.), MAO inhibitors, sympathomimetics, antidepressants, hypnotics, any benzodiazepines, antiepileptics, opioids, clonidine, magnesium, ferrous salts, folic acid, vitamin B12, antihistaminics, lithium, melatonin.
- •Patients with diabetes mellitus requiring insulin therapy.
- •Patients with microcytic anemia at investigators discretion.
- •History or clinical signs of peripheral neuropathy (PNP) of any origin in physical, neurological examination, myelopathy or multiple sclerosis or any other neurological disease, with potential to secondarily cause RLS symptoms.
- •Other sleep disorder, such as, REM sleep behaviour disorder, narcolepsy or sleep apnea syndrome (with AHI >15 at Visit 3, or a history of loud snoring occurring at least 5 nights a week combined with a history of breathing pauses during sleep and excessive daytime sleepiness).
- •Clinically significant renal disease or creatinine higher than upper limit of normal (ULN) at screening.
结局指标
主要结局
Primary Endpoint: Decrease in periodic limb movements during time in bed index (PLMI) in the PSG
次要结局
- Total score of RLS severity scale-J by IRLSSG, Periodic Limb Movements during Sleep Index (PLMSI) in the PSG Periodic Limb Movements during Wakefulness Index (PLMWI) in the PSG Periodic Limb Movements in Sleep with Arousal Index (PLMAI) in the PSG )
研究者
研究点 (7)
Loading locations...
相似试验
进行中（未招募）
1 期
Evaluating the Safety, Tolerability, and Pharmacokinetics of DF-003 in Healthy SubjectsHealthySafety and TolerabilityNCT05997641Shanghai Yao Yuan Biotechnology Ltd. (also known as Drug Farm)96
进行中（未招募）
1 期
ot applicableMetastatic Castrate-refractory Prostate CancerMedDRA version: 18.1Level: PTClassification code 10036909Term: Prostate cancer metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2011-006314-14-CZCureVac AG200
进行中（未招募）
1 期
ot applicableMetastatic Castrate-refractory Prostate CancerMedDRA version: 19.0Level: PTClassification code 10036909Term: Prostate cancer metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2011-006314-14-DECureVac AG200
进行中（未招募）
1 期
A Phase 2 Study to Assess the Efficacy and Safety of Orally Administered DS107 in a once daily doseof 2g in Haemodialysis Patients with Moderate to Severe Uremic PruritusModerate to Severe Uremic PruritusMedDRA version: 20.0Level: LLTClassification code 10060884Term: Uremic pruritusSystem Organ Class: 100000004858EUCTR2017-004098-15-EEDS Biopharma110
招募中
3 期
Olaparib Maintenance Monotherapy in Participants with BRCA Wild Type Ovarian Cancer Following Response to First-line Platinum-based chemotherapyCTRI/2021/08/035759AstraZeneca AB